We are live on
!
Find out more
CC
Commodore Capital Portfolio holdings
AUM
$1.68B
1-Year Est. Return
375.52%
This Fund
S&P 500
This Quarter
Est. Return
+48.18%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$2.05B
AUM Growth
+$632M
(+45%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
5.52%
Top 10 Holdings %
Top 10 Hldgs %
58.91%
Holding
40
New
7
Increased
9
Reduced
9
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$58.5M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$54.9M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$38.4M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$36.4M |
| 5 |
LBRX
LB Pharmaceuticals
LBRX
|
+$23.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$51.4M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$37.6M |
| 3 |
Viridian Therapeutics
VRDN
|
+$30.2M |
| 4 |
Vera Therapeutics
VERA
|
+$18.8M |
| 5 |
DFTX
Definium Therapeutics
DFTX
|
+$16.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.61% |
| 2 | Financials | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CytomX Therapeutics
CTMX
$771M
| $24.5M | 1.2% |
7,692,300
| – | – |
|
|
LBRX
27
LB Pharmaceuticals
LBRX
$1.54B
| $23.7M | 1.16% |
+1,500,000
| New | +$23.8M |
|
28
Tango Therapeutics
TNGX
$4.05B
| $12.6M | 0.62% |
1,500,000
| – | – |
|
|
APGE
29
DELISTED
Apogee Therapeutics
APGE
| $11.5M | 0.56% |
290,000
| – | – |
|
30
PepGen
PEPG
$218M
| $10.9M | 0.53% |
+2,357,319
| New | +$3.8M |
|
31
Enanta Pharmaceuticals
ENTA
$386M
| $9.58M | 0.47% |
+800,000
| New | +$6.39M |
|
32
SAB Biotherapeutics
SABS
$317M
| $8.85M | 0.43% |
+4,401,500
| New | +$9.95M |
|
33
Inhibikase Therapeutics
IKT
$336M
| $8.74M | 0.43% |
5,397,488
| – | – |
|
|
PCSC
34
DELISTED
Perceptive Capital Solutions
PCSC
| $7.92M | 0.39% |
750,000
| – | – |
|
35
Avalo Therapeutics
AVTX
$977M
| $6.14M | 0.3% |
483,000
| – | – |
|
36
VistaGen Therapeutics
VTGN
$10.5M
| $5.59M | 0.27% |
1,575,000
| – | – |
|
|
CBIO
37
Crescent Biopharma
CBIO
$743M
| $5.36M | 0.26% |
450,829
-2,857
| -0.6% | -$37.9K |
|
38
Neurogene
NGNE
$758M
| – | – |
-427,866
| Closed | -$6.4M |
|
|
39
Scholar Rock
SRRK
$6.65B
| – | – |
-1,450,000
| Closed | -$51.4M |
|
|
40
Vera Therapeutics
VERA
$2.43B
| – | – |
-800,000
| Closed | -$18.8M |
|
Similar funds
TNBTD
PWMAG
SH
CC
BCLSI
TP
ICM
HCA
Commodore Capital's Q3 2025 Portfolio in Review
As of Q3 2025, Commodore Capital held 40 positions worth $2.05B, up 45% from $1.42B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Commodore Capital deployed $113M of net new capital in Q3 2025, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 4,075,478 shares worth $55.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Cidara Therapeutics, an estimated $37.6M trimmed.
- Commodore Capital's largest Q3 2025 buy was Amylyx Pharmaceuticals: 4,075,478 shares worth $55.4M.
- Commodore Capital added most to Cogent Biosciences in Q3 2025, an estimated $58.5M increase.
- Commodore Capital's biggest Q3 2025 reduction was Cidara Therapeutics, cutting an estimated $37.6M.
- Commodore Capital fully exited Scholar Rock in Q3 2025, selling an estimated $51.4M.
- Commodore Capital's ten largest holdings make up 59% of its $2.05B portfolio in Q3 2025.
- Commodore Capital opened 7 new positions and closed 3 in Q3 2025.
- Commodore Capital's portfolio value rose 45% quarter-over-quarter to $2.05B.
Based on Commodore Capital's 13F filing for Q3 2025, filed 14 Nov 2025.